Skip to main content

Day: August 26, 2024

Futu Announces Investment Grade Rating Reaffirmed by S&P Global Ratings

HONG KONG, Aug. 26, 2024 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced that S&P Global Ratings (“S&P”) maintained stable outlook on the long-term rating and reaffirmed the Company’s long-term issuer credit rating at “BBB-”. Futu’s securities firm in Hong Kong has a stand-alone credit profile of “bbb”. According to S&P, Futu enjoys a strong market position in Hong Kong and is expected to maintain good growth momentum in its overseas business. Additionally, S&P takes the view that Futu will continue to uphold its strong capitalization and robust funding profile to support its business growth. About Futu Holdings Limited Futu Holdings Limited (Nasdaq: FUTU) is an advanced technology company...

Continue reading

Danske Bank share buy-back programme: Transactions in week 34

Company announcement no. 37 2024  Group CommunicationsBernstorffsgade 40DK-1577 København VTel. +45 45 14 00 00 26 August 2024Danske Bank share buy-back programme: Transactions in week 34 On 2 February 2024, Danske Bank A/S announced a share buy-back programme for a total of DKK 5.5 billion, with a maximum of 70 million shares, in the period from 5 February 2024 to 31 January 2025, at the latest, as described in company announcement no. 2 2024. The programme is being carried out under Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Rules. The following transactions were made under the share buy-back programme in week 34:  Number of shares VWAP DKK Gross valueDKKAccumulated,...

Continue reading

IDEX Pay biometric card solution certificated by Visa

Oslo, Norway – 26 August 2024 – IDEX Biometrics has reached an important milestone for IDEX Pay by successfully passing Visa’s certification using Visa’s latest VBSS(*) biometric payment application. The IDEX Pay biometric solution includes the IDEX Biometrics proprietary card operating system and latest technology fingerprint sensor with Infineon’s high performing SLC38 secure element. The Visa certification is the ultimate result of comprehensive biometric performance testing and ensures that payment’s scheme functional and security specifications are met. This certification confirms that IDEX Pay is ready for scaled commercialization on the Visa payment network. With more than 3 billion Visa cards in circulation and with a leading market position in key growth market in APAC, Latin America and Africa, this certification enables card...

Continue reading

Transactions by persons discharging managerial responsibilities and/or persons close associated

COMPANY ANNOUNCEMENT NO 16/2024 – August 26, 2024 Royal Unibrew A/S hereby makes public pursuant to article 19(3) of regulation (EU) no. 596/2014 of the European Parliament and of the Council on market abuse the information on the below transaction related to shares in Royal Unibrew A/S made by persons discharging managerial responsibilities in Royal Unibrew A/S and/or persons closely related with them.1 Details of the person discharging managerial responsibilities/person closely associateda) Name Lise Mortensen2 Reason for the notificationa) Position/statusBoard member of Royal Unibrew A/Sb) Initial notification / Amendment Initial notification3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora) Name Royal Unibrew A/Sb) LEI 529900D69KFL8IAP8Q634 Details...

Continue reading

Offentliggørelse af prospekt samt formue og investorer for afdelingen I&T Globale Aktier ESG Select i Investeringsforeningen Wealth Invest

Hermed offentliggøres prospekt samt formue og antal investorer for afdelingen I&T Globale Aktier ESG Select, som optages til handel på Nasdaq Copenhagen A/S med første handelsdag 28. august 2024.Afdeling Formue DKK Antal navnenoterede investorerI&T Globale Aktier ESG Select   897.505.614 452Hvis der måtte være spørgsmål i relation til ovenstående, kan der rettes henvendelse til direktør i Investeringsforvaltningsselskabet SEBinvest A/S, Lise Bøgelund Jensen på telefon 3328 2828.  Med venlig hilsen Investeringsforeningen Wealth InvestAttachment2024 08 26 Børsprospekt WI I&T_FINAL

Continue reading

Thomas Olsen to leave Suominen, Markku Koivisto appointed interim EVP, Americas

Suominen Corporation’s stock exchange release on August 26, 2024 at 10:00 a.m. (EEST) Mr. Thomas Olsen, EVP Americas, will leave Suominen to pursue new opportunities outside the company. Mr. Markku Koivisto has been appointed as interim EVP, Americas in addition to his current role as EVP, EMEA and CTO. The change is effective as of today. The process to recruit a new EVP, Americas will be started immediately. “I want to thank Thomas for his contribution in leading the Americas business area and for being a valuable member of our Executive Management Team,” says Tommi Björnman, President and CEO of Suominen. SUOMINEN CORPORATIONCorporate Communications For more information, please contact:Tommi Björnman, President & CEO, tel. +358 10 214 3018 Suominen manufactures nonwovens as roll goods for wipes and other applications. Our vision...

Continue reading

Lung Cancer mRNA Vaccine Clinical Trials FDA EMA Approval Commercial Opportunity Insight

First Commercial Availability Of mRNA Cancer Vaccine Is Expected To Be Available By 2029 Says Kuick Research Delhi, Aug. 26, 2024 (GLOBE NEWSWIRE) — Global mRNA Cancer Vaccines Clinical Trials and Market Future Outlook 2024 Report Highlights:mRNA Cancer Vaccines In Clinical Trials: > 60 Vaccines Highest Phase Of Clinical Trials: Phase III ( 2 Vaccine) mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication and Phase First Commercial mRNA Vaccine Approval Expected By 2029 US and China Dominating mRNA Cancer Vaccines Clinical Trials: > 45 Vaccines mRNA Vaccines For Skin Cancer Dominating Trials: > 10 VaccinesDownload Global mRNA Cancer Vaccines Clinical Trials Report: https://www.kuickresearch.com/report-mrna-cancer-vaccine-rnca-vaccine-mrna-cancer-vaccine-market-fda-approved-mrna-cancer-vaccine-mrna-cancer-vaccine-clinical-trials-mrna-cancer-vaccines Lung...

Continue reading

Volt Lithium Successfully Installs Field Unit in Permian Basin and Scales-Up Production Capacity to Over 200,000 Litres (1,250 Barrels) per Day

Deployed and installed its first proprietary direct lithium extraction (“DLE”) U.S. field unit (“Field Unit”) Commenced function-testing of the Field Unit, paving the way for first lithium production Scaled-up Field Unit by more than two times to process over 200,000 litres (1,250 barrels) of oilfield brine per day on location in West Texas, USACALGARY, Alberta, Aug. 26, 2024 (GLOBE NEWSWIRE) — Volt Lithium Corp. (TSXV: VLT | OTCQB: VLTLF I FSE: I2D) (“Volt” or the “Company“) announces the successful deployment, installation and commenced function-testing of its first Field Unit located in the Permian Basin in Texas, paving the way for first lithium production. The Company is also pleased to announce that the Field Unit will be capable of processing over 200,0001 litres (1,250 barrels) of oilfield brine...

Continue reading

Multispecific Antibody Therapeutics Clinical Trials FDA Approved Multispecific Antibodies Market Size Insight

Multispecific Antibodies Market Size To Surpass USD 40 Billion In By 2029 Says Kuick Research Delhi, Aug. 26, 2024 (GLOBE NEWSWIRE) — Multispecific antibody therapeutics are rapidly emerging as a transformative approach in the treatment of various diseases, particularly cancer, autoimmune disorders, and infectious diseases. Unlike traditional monoclonal antibodies that target a single antigen, multispecific antibodies are designed to engage multiple targets simultaneously. This capability allows them to modulate complex biological pathways, offering enhanced therapeutic efficacy and the potential to overcome limitations associated with single-target therapies. The concept of multispecific antibody therapeutics stems from the need to address diseases with multifaceted pathologies. For instance, in cancer, tumors often employ multiple...

Continue reading

Sampo plc’s share buybacks 23 August 2024

SAMPO PLC                 STOCK EXCHANGE RELEASE                  26 August 2024 at 8:30 am Sampo plc’s share buybacks 23 August 2024 On 23 August 2024, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  4,535 40.42 AQEU          37,854 40.42 CEUX  693 40.44 TQEX  53,742 40.41 XHELTOTAL 96,824 40.41  *rounded to two decimals                 On 17 June 2024, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.